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Summary
Macroautophagy (hereafter referred to as autophagy) is a
highly conserved, intracellular degradation process char-
acterised by de novo formation of autophagosomes.
These double membraned organelles engulf and deliver
cargo, for example damaged organelles and protein ag-
gregates, to lysosomes for degradation and recycling. Au-
tophagy is primarily a stress response mechanism activat-
ed to survive unfavourable conditions such as starvation
or hypoxia. In addition, autophagy functions in differen-
tiation, immune responses against invading microorgan-
isms and tissue remodelling in mammalian cells. Besides
its cytoprotective nature, and depending on the context,
autophagy can as well support cell death. Based on au-
tophagy’s cytoprotective, cytotoxic and developmental in-
fluences, it does not come as a surprise that this mech-
anism is involved in tumourigenesis, tumour development
and the response to anticancer therapies. HER2 is a re-
ceptor tyrosine kinase that activates downstream sig-
nalling pathways involved in cellular survival, growth and
proliferation. Amplification of the gene and subsequent
overexpression of the HER2 protein lead to increased ac-
tivation of downstream signalling and are implicated in
several cancer types. HER2-targeted therapies are valu-
able treatment options for HER2 amplified cancers. How-
ever, pre-existing and acquired resistance remain a clini-
cal challenge. Autophagy has been discussed in several
scenarios in HER2 amplified cancers. Generally, HER2+
tumours have been shown to exhibit low levels of proteins
essential for autophagy. Moreover, a protein involved in
autophagy activation, Beclin-1, was shown to interact di-
rectly with HER2 at the cellular membrane. The signalling
cascade activated by HER2 also activates mTOR, a neg-
ative regulator of autophagy. In the context of resistance
formation against HER2-targeting treatment, autophagy
has often been reported to be upregulated, and resistance
has been shown to be abrogated through autophagy inhi-
bition. Since the autophagy inhibitors chloroquine and hy-
droxychloroquine are approved drugs for the treatment of
malaria, autophagy inhibition is discussed as an option to
enhance the effect of certain anticancer treatments or to
overcome resistance against cancer therapies. In this re-
view we focus on autophagy and its role in the response
to HER2-targeted therapies for breast and gastrointestinal
tumours.
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Autophagy
Macroautophagy, often simply referred to as autophagy, is
a multistep process involved in cellular homeostasis and
adaptation to stress conditions. As a catabolic process,
autophagy maintains the nutrient homeostasis of the cell
and participates in the quality control of proteins and or-
ganelles [1]. Upon cellular stress, for instance by starva-
tion, hypoxia, genotoxic or proteotoxic stress, autophagy
is upregulated as an adaptive cell response [2, 3]. The
process is characterised by the formation of a double mem-
braned vesicle, the autophagosome, which engulfs cyto-
plasmic material. The autophagosome fuses with the lyso-
some, which ultimately leads to the degradation of its
content. In the lysosome, proteins are degraded by cathep-
sins, which are a group of proteases activated at low pH
values typical of lysosomes [4]. Thus, the content of the
so-called autolysosome is recycled for biosynthesis and/or
energy production. The macroautophagic pathway is divid-
ed into distinct steps (fig. 1): (a) nucleation of the isola-
tion membrane, (b) expansion of the membrane, (c) closure
and maturation of the autophagosome, (d) fusion of the au-
tophagosome with the lysosome, and (e) degradation and
recycling of the delivered cargo [5, 6]. The evolutionari-
ly conserved degradation pathway involves at least 16–20
core autophagy (ATG) genes. The ATG proteins encoded
by these genes are classified into functional groups that act
at different stages of autophagy [7, 8].
One of the important players in this multistep process is
unc-51-like autophagy activating kinase 1 (ULK1, the
mammalian orthologue of yeast ATG1). It is the activating
kinase in the autophagy initiating complex [9, 10]. The
phosphorylation of downstream players by this complex
leads to the elongation of the isolation membrane and al-
lows the recruitment of another multiprotein complex con-
taining Beclin-1 and the catalytic subunit VPS34 [11, 12].
Beclin-1 is monoallelically deleted or downregulated in
various tumour types, such as breast and ovarian cancer,
indicating its tumour suppressor function [13, 14]. The iso-
lation membrane elongates through incorporation of phos-
pholipids from different sources, such as the endoplasmic
reticulum (ER). As autophagy is a dynamic process, it is
difficult to capture the actual “autophagic flux” describing
the rate of degradation by using only ATG gene expression
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data. Therefore, the microtubule-associated protein light
chain 3B (LC3B) is frequently used as an autophagy mark-
er. The LC3B protein is processed during active autophagy.
As an ATG8 family member, it is lipidated to LC3B-II and
then integrated into the growing autophagosomal mem-
brane by its conjugation to phosphatidylethanolamine.
LC3B-II enables the elongation of the isolation membrane
as well as cargo recruitment [15, 16]. The non-lipidated
LC3B-I and the lipidated LC3B-II can be differentiated by
Western blotting. Thus, increasing autophagosome forma-
tion can be visualised via Western blotting and indicated by
higher LC3B-II to LC3B-I ratios. Additional LC3B-based
techniques include assessment of LC3B dot formation up-
on ectopic expression of GFP-LC3B or of endogenous
LC3B, using immunofluorescent microscopy or immuno-
histochemistry [17].
Under certain conditions, such as starvation, autophagy
is rather unspecific. In the last decade, however, specific
degradation of cargo by macroautophagy, so-called selec-
tive autophagy, has been described. Different cargos, such
as mitochondria, lipid droplets, ribosomes, protein aggre-
gates or individual proteins can be degraded via selective
autophagy with the help of cargo receptors. These cargo
adaptor proteins directly link the cargo to the autophago-
some. In most cases the cargo either contains a so-called
LC3-interacting region (LIR) that can bind to LC3B or the
cargo is labelled with a ubiquitin tag. In the latter case,
the degradation is mediated by an adapter protein that has
a ubiquitin binding site as well as an LIR [18]. Sequesto-
Figure 1: Schematic presentation of macroautophagy, chaperone-mediated autophagy (CMA) and microautophagy. On the left hand
side, an overview of macroautophagy is depicted in red. The isolation membrane forms during the nucleation process. An important player in
nucleation and elongation is the Beclin-1 core complex. During the elongation of the double membrane LC3B is lipidated and allows the bind-
ing of adaptor proteins such as p62. After autophagosome closure, the autophagosome fuses with the lysosome, followed by degradation and
recycling of its contents. The degradation is mediated by cathepsins. These proteases become activated in the low pH found in lysosomes. In
the middle of the diagram, microautophagy, a process characterised by the direct uptake of cytosolic material into the lysosome, is depicted.
On the right, the chaperone mediated autophagy (CMA) pathway is outlined. In this process, proteins containing a KFERQ amino acid se-
quence motif are recognised by a chaperone complex containing HSC70. The complex is then translocated to the lysosome and, with the help
of the LAMP2A complex, incorporated into the lysosome and degraded.p62 = sequestosome 1, SQSTM1; LC3B = microtubule-associated pro-
tein light chain 3B; HSC70 = heat shock 70 kDa protein 8; LAMP2A = lysosome-associated membrane protein 2A
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some 1 (SQSTM1, also known as p62) represents just such
an autophagy adaptor that targets cargo to the growing au-
tophagosomal membrane. P62 is degraded together with
the cargo, which allows using degradation of p62 as a
marker for autophagic flux [19, 20].
Besides macroautophagy there are at least two additional
forms of autophagy, namely chaperone mediated au-
tophagy (CMA) and microautophagy. These three path-
ways differ in the way the cargo is delivered to the lyso-
some (fig. 1). During CMA, cytosolic proteins are
recognised by heat shock 70 kDa protein 8 (HSC70)
through a specific amino acid sequence, the so-called
KFERQ motif. Subsequently, the protein is shuttled to the
lysosome and is finally translocated via another protein
complex including lysosome-associated membrane protein
2A (LAMP2A) into the lysosome (fig. 1) [21, 22]. Mi-
croautophagy is characterised by the direct lysosomal up-
take of cytoplasmic entities [23].
In addition to its role in homeostasis and stress adaptation,
autophagy also plays a role in cellular differentiation, im-
mune response against invading microorganisms or tissue
remodelling [24, 25]. Aberrant autophagy has been report-
ed in connection with various diseases, such as inflamma-
tion, cancer formation or neurodegeneration [2, 26]. In this
context it is important to mention that autophagy and apop-
tosis are closely linked. The anti-apoptotic protein Bcl-2,
which is often upregulated in cancer, directly interacts with
the key autophagy gene Beclin-1. By binding and seques-
tering Beclin-1 and thus inhibiting it from initiating au-
tophagy, Bcl-2 acts as a negative regulator of autophagy
[27]. Moreover, additional ATG proteins, such as ATG5 or
ATG12, interact with Bcl-2 family members, indicating a
complex crosstalk between the two pathways [28, 29].
To summarise, the term autophagy describes several lyso-
somal degradation pathways that differ in their cargo de-
livery to the lysosome. The best-studied form of autophagy
is macroautophagy. The conserved multistep process is
responsible for cellular homeostasis at basal conditions
and can be upregulated upon different cellular stresses. In
recent years, macroautophagy has been shown not only
to perform bulk degradation but also to exert high cargo
specificity. The cellular stress response mechanism au-
tophagy is interconnected with apoptosis, and aberrant au-
tophagy has been linked to various diseases.
Autophagy and cancer
Autophagy plays a dual role in cancer development and
progression. Autophagy guards cellular homeostasis and
therefore contributes to the prevention of malignant trans-
formation. On the other hand, it seems to play a rather tu-
mour-promoting role in established tumours (fig. 2) [30].
Evidence to support a tumour suppressor function of au-
tophagy stems from murine models defective in essential
autophagy genes. For instance, Beclin-1+/- animals sponta-
neously develop malignancies such as lymphomas or lung
carcinomas [31, 32]. Moreover, mice with liver-specific
knockout of Atg7 or a systemic mosaic deletion of Atg5
develop benign hepatic neoplasms [33]. Additionally, au-
tophagy suppresses the accumulation of genetic and ge-
nomic defects caused by reactive oxygen species (ROS)
through removal of dysfunctional mitochondria and redox-
active aggregates of ubiquitinated proteins [34, 35]. More-
over, by eliminating dysfunctional mitochondria au-
tophagy ensures optimal energy supply, which counteracts
the metabolic rewiring often observed during malignant
transformation [35]. Further, autophagy is involved in the
maintenance of normal stem cells. The above-mentioned
Beclin-1+/- mice, for example, show an expansion of prog-
enitor-like mammary epithelial cells [36, 37]. Autophagy
is also involved in the degradation of aggregate-prone
oncogenes, such as forms of mutated TP53, p62, PML-
RARA or BCR-ABL1 [34, 38–40]. It is required in several
aspects of anticancer immunosurveillance, and thus in the
elimination of potentially tumourigenic cells by the im-
mune system [41]. Additionally, autophagy plays a key
role in first line defence against bacterial or viral infection.
Multiple potentially carcinogenic pathogens, such as Sal-
monella enterica, Helicobacter pylori or Chlamydia pneu-
moniae, can activate autophagy upon infection [42–45].
There are indications that the activation of oncoproteins,
and, similarly, the inactivation of tumour suppressor pro-
teins can attenuate autophagy. This reduced autophagic
activity supports early phases of oncogenesis [46]. Anti-
apoptotic Bcl-2 family members, such as Bcl-2 or Bcl-XL,
that are upregulated in various cancer types, also inhibit
autophagy through sequestration of Beclin-1 [27]. MDM2
represents another proto-oncogene that negatively affects
autophagy. High MDM2 levels inactivate the TP53 tumour
suppressor. Inactivated TP53 then fails to activate tran-
scription of its target ATG genes [47]. Furthermore, sever-
al receptor tyrosine kinases (RTKs), such as the epidermal
growth factor receptor (EGFR) or v-erb-b2 avian erythrob-
lastic leukaemia viral oncogene homologue 2 (ERBB2, al-
so known as HER2), or downstream signal transducers
that are often overexpressed in solid tumours inhibit au-
tophagy by activating its negative regulator mTORC1 [48].
The tumour suppressor phosphatase and tensin homologue
(PTEN) is often inactivated in cancers. This phosphatase
promotes autophagy by antagonising PI3K signalling that
negatively regulates autophagy [49]. The transcription fac-
tor forkhead box O1 (FOXO1) represents another tumour
suppressor essential for stress-induced autophagy that is
mutated in diffuse large B-cell lymphomas [50].
In neoplastic cells, however, restored autophagy response
allows cancer cells to cope with intracellular and envi-
ronmental stress (fig. 2, right panel) [51, 52]. Thus, in
advanced human tumours high autophagic flux correlates
with an invasive, metastatic phenotype and poor survival
rates [53]. In mouse experiments, highly metastatic hepa-
tocellular carcinoma cell lines with inhibited Beclin-1 or
Atg5 expression are unable to survive in the metastatic
niche, in contrast to their autophagy-competent counter-
parts [54]. In KRAS-driven pancreatic adenocarcinoma
cells, autophagy is upregulated upon oncogene ablation to
counterbalance the metabolic stress occurring upon shut-
down of oncogenic KRAS signalling [55]. Breast cancer
stem cells from mammosphere cultures are also charac-
terised by elevated autophagic flux. Importantly, their abil-
ity to form tumours in vivo seems to depend on proficient
autophagy, as they are not able to form tumours upon
genetic inhibition of Beclin-1 or ATG4A [56, 57]. Au-
tophagy-deficient tumours are generally more sensitive to
chemotherapeutic agents and to radiotherapy compared
with their autophagy-proficient counterparts [58, 59].
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Senescent cancer cells, which do not proliferate but can
still support relapse by influencing the tumour microenvi-
ronment, depend on autophagy for survival [60].
In summary, autophagy in healthy cells prevents tumour
development, and its downregulation may contribute to
early oncogenesis. In late tumour development cancer cells
hijack autophagy to play instead an oncogenic role (fig. 2).
In this context, autophagy can protect cancer cells from an-
ticancer treatment and may thus contribute to therapy re-
sistance.
Several compounds that inhibit autophagy at different
stages are known. The only clinically approved autophagy
inhibitor is the antimalarial drug chloroquine and its de-
rivative hydroxychloroquine. These drugs interfere with
lysosomal acidification and thus prevent the degradation
of autophagosomes [61, 62]. Hydroxychloroquine is pre-
ferred over chloroquine in clinical trials owing to its lower
toxicity [63, 64]. Several preclinical in vitro and in vivo
studies have shown an antineoplastic effect of hydrox-
ychloroquine in combination with various clinically ap-
proved drugs [65]. However, the use of chloroquine and
hydroxychloroquine as autophagy inhibitors is controver-
sial, since both reagents exert autophagy inhibition-inde-
pendent effects as well. Thus, chloroquine can sensitise
cancer cells to chemotherapeutic drugs independent of au-
tophagy inhibition [66, 67]. This was illustrated in a 2012
study, where chloroquine was used to sensitise mouse
breast cancer cells to several established anticancer treat-
ments. The observed sensitisation was independent of au-
tophagy inhibition as it could not be mimicked with
ATG12 or Beclin-1 knockdown or treatment with
Bafilomycin A1 (BafA), another autophagy inhibitor [66].
Furthermore, a preclinical study evaluating the pharma-
codynamics of hydroxychloroquine in pet dogs with lym-
phoma showed that the plasma concentration of hydroxy-
chloroquine does not correlate with drug concentration in
the tumours. This discrepancy consequently also applies
to the extent of autophagy inhibition in the tumour tissue
[68]. Another open question concerning the use of chloro-
quine and hydroxychloroquine as autophagy inhibitors in
the clinic is whether it is better to block the process at
early or at late autophagy stages. Early autophagosomal
structures can serve as scaffolds for inducing apoptosis and
necroptosis. Thus, the accumulation of autophagosomes
could promote these pathways in some cases [69]. Since
chloroquine and hydroxychloroquine inhibit autophagy at
a late stage, and their mechanism of action is not well un-
derstood, new specific inhibitors with improved pharma-
codynamics that also target early autophagy kinases, such
as VPS34 or ULK1, are being developed and evaluated in
preclinical studies [70, 71].
Human epidermal growth factor receptor 2
(HER2) and its role in human cancers
HER2 (also known as ERBB2) is a transmembrane recep-
tor tyrosine kinase of the EGFR (epidermal growth fac-
tor receptor) family, consisting of EGFR (ERBB1), HER2
(ERBB2), HER3 (ERBB3) and HER4 (ERBB4) [72, 73].
These receptor tyrosine kinases act in the epithelium as
signal transducers between mesenchymal and epithelial
cells. The EGFR receptors form homo- and heterodimers
which transphosphorylate each other upon activation. This
further stimulates intracellular downstream pathways, such
as mitogen-activated protein kinase (MAPK) signalling
Figure 2: The Janus-faced role of autophagy in cancer. In healthy cells macroautophagy has a tumour suppressor function. As a catabolic
survival mechanism, it ensures optimal energy supply, preserves genetic and genomic stability, maintains normal stem cells, is involved in the
degradation of oncogenes, and is the first line defence against bacterial or viral infection. During tumour formation downregulation of au-
tophagy is frequently observed, possibly supporting tumor development. In established tumours, however, autophagy functions can be re-
stored and instead support tumour development. This occurs, for example, via (a) supporting EMT and metastasis, (b) rendering cells resistant
to anoikis (programmed cell death upon detachment), (c) counteracting metabolic and oxidative stress, (d) maintaining cancer stem cells and
supporting the senescent cell state, and (e) promoting chemo- as well as radiotherapy resistance.
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cascades RAS/MEK/ERK, PI3K/AKT/TOR or STAT tran-
scription factors, that are involved in proliferation, survival
and differentiation [74, 75]. Examples of ligands shed by
the mesenchyme are Neuregulins that bind to HER3 and
HER4. Although HER2 is the most potent oncogene of
the family, to date no high affinity ligand for HER2 has
been found. However, its conformation resembles a ligand-
activated state, which favours dimerisation [76, 77]. This
makes HER2 the preferred dimerisation partner for the oth-
er three family members [78]. As the signalling system
may be fine-tuned by the partners of the heterodimer, the
abundance of HER2 is crucial. Importantly, the
HER2-HER3 heterodimer is the most transforming and mi-
togenic heterodimer of the EGFR family [79, 80]. The po-
tent proliferation signalling generated by the EGFR net-
work is often corrupted in cancer cells. Overexpression
or constitutive action of the individual receptors is ob-
served in a variety of tumours [81]. HER2 is overexpressed
in several types of tumours such as breast, gastric, oe-
sophageal, lung, bladder or endometrial cancer [82]. How-
ever, in breast cancer the association of ERBB2 amplifi-
cation and subsequent overexpression of HER2 is the best
studied. About 20% of breast tumours show ERBB2 gene
amplification [83]. The amplification correlates with high
risk of recurrence and disease-related death and thus a poor
prognosis [84, 85]. HER2+ tumours form a separate sub-
class of breast cancer that is eligible for HER2-targeted
treatment. These tumours are typically oestrogen receptor
negative. Moreover, HER2 expression is the most impor-
tant predictive factor for response to HER2-targeted thera-
pies [86]. Similarly, HER2 overexpression correlates with
pathological features such as lymphatic invasion, high
grade or large tumour size in gastric cancer [87]. Besides
the ERBB2 amplification, somatic mutations are observed
in several tumour types, such as breast, lung, gastric and
bladder cancer. Most of these mutations are missense mu-
tations in the tyrosine kinase or extracellular domain, ren-
dering the receptor constantly active [88].
HER2-targeted therapies
HER2-targeting drugs to treat HER2+ tumours can be di-
vided into two classes: (a) HER2-directed antibodies, such
as trastuzumab, and (b) small-molecule inhibitors targeting
the kinase activity of the receptor, such as lapatinib [89].
Trastuzumab is a humanised antibody that binds an extra-
cellular epitope of HER2. Binding of the antibody uncou-
ples HER2-containing dimers, which leads to partial inhi-
bition of downstream signalling. In addition, trastuzumab
induces antibody-dependent cell-mediated cytotoxicity
(ADCC) [90–92]. As early as 1998, trastuzumab was ap-
proved for metastatic breast cancer, and in 2006 approval
for adjuvant therapy of early breast cancer followed.
Trastuzumab has been successfully integrated into stan-
dard therapy for HER2+ breast cancer, either in a periop-
erative or metastatic setting [93–96]. In 2010, trastuzumab
was approved for advanced gastric and gastro-oesophageal
cancer. Previously, the ToGa (trastuzumab for gastric can-
cer) study showed a significant overall survival benefit for
patients with metastatic HER2+ gastric cancer when the
drug was added to standard chemotherapy [97]. A new
generation of HER2 antibody, pertuzumab, recognises a
different epitope of HER2. Its binding leads to the block-
age of ligand-induced HER2-HER3 dimerisation and thus
inhibits partially downstream signalling [98]. As
trastuzumab and pertuzumab target different epitopes, the
combination of the two antibodies showed a synergistic ef-
fect in preclinical studies and clinical trials [99–101]. Since
2012, pertuzumab has been approved for the treatment of
HER2+ metastatic breast cancer [102]. Another derivative
of trastuzumab is trastuzumab emtansine (T-DM1). This is
an antibody-drug conjugate whereby trastuzumab is bound
to maytansinoid, a drug inhibiting microtubule polymerisa-
tion [103]. This new antibody-drug conjugate binds to the
epitope with an affinity similar to trastuzumab, and, in ad-
dition to blocking signal transduction and induction of AD-
CC, the drug mediates the inhibition of microtubules [104].
In 2013, T-DM1 was approved for advanced HER2+ breast
cancer [105].
In contrast to trastuzumab, lapatinib is a small-molecule
kinase inhibitor that binds reversibly to the ATP-binding
side of EGFR and HER2. Lapatinib disables HER2 down-
stream signalling, being effective even in HER2+ cancers
that have progressed after trastuzumab treatment. Lapa-
tinib was approved for the treatment of advanced breast
cancer in 2006 [106]. Further developed derivatives are
afatinib and neratinib. Both small-molecule inhibitors bind
irreversibly to the ATP-binding site of RTKs. Whereas ner-
atinib binds only to HER2, afatinib binds to both HER2
and EGFR [107, 108]. Neratinib was approved for the ad-
juvant treatment of HER2+ breast cancer after trastuzum-
ab progression in 2017 [109]. Afatinib, as a dual EGFR-
HER2 inhibitor, is approved for the treatment of
non-small-cell lung carcinoma [110]. Besides the consid-
erable success of HER2-targeting drugs and their improve-
ments, resistance formation remains a clinical challenge.
Resistance mechanisms against HER2 inhibi-
tion
Although HER2-targeting treatment provides considerable
benefit for patients with HER2+ tumours, most tumours ul-
timately progress to treatment resistance [111]. Resistance
may be pre-existing or drug-induced (acquired). Generally,
pre-existing resistance tends to occur through alterations
of the receptor itself or modifications of downstream sig-
nalling pathways [112, 113]. On the other hand, acquired
resistance is more diverse. Here, resistance instead occurs
through bypass mechanisms as increased expression of
other family members (EGFR, HER3) or different receptor
tyrosine kinases, such as hepatocyte growth factor receptor
(MET) [114–116]. It is important to mention that all the re-
sistance mechanisms described above can be the cause of
pre-existing as well as of acquired resistance [117–119].
Expression of a truncated form of HER2, so-called
p95-HER2, which lacks the trastuzumab binding epitope,
represents an alteration of the HER2 receptor mediating
treatment resistance [113, 120]. P95-HER2 is associated
with low response rates to trastuzumab. However, since
the kinase activity of the receptor remains intact, these tu-
mours are still sensitive to kinase inhibitors such as la-
patinib [121]. Another HER2 alteration that mediates re-
sistance is an ERBB2 gene splice variant lacking exon
16. These receptors retain the epitopes recognised by
trastuzumab, but HER2 homodimers containing this iso-
form are more stable than their wild-type counterparts.
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Therefore, trastuzumab-mediated disruption of the homod-
imers is circumvented and the homodimers remain activat-
ed to stimulate downstream targets such as Src kinase [122,
123].
Another family of resistance mechanisms consists of so-
called bypass track pathways. Here, downstream signalling
pathways are kept activated by mechanisms “bypassing”
the inhibited receptor tyrosine kinase [124]. Examples are
the amplification of MET or the enhanced stimulation of
MET by its ligand, hepatocyte growth factor (HGF) [125].
Similarly, upregulation of EGFR and/or HER3 renders
cancer cells resistant to HER2-targeting treatment. In this
scenario, more active EGFR/HER3 receptors are available
that activate downstream signalling pathways [126]. More-
over, aberrantly activated intracellular kinases of the HER2
signalling pathway can bypass HER2 inhibition. Promi-
nent examples are mutations in the phosphatidylinositol
3-kinase (PI3K) pathway. Such alterations are observed
in about 30% of HER2+ breast cancer patients [127]. Pa-
tients bearing PI3K catalytic subunit alpha (PI3KCA) gene
mutations do not benefit from HER2-targeting therapies.
As was shown in the randomised phase III EMILIA and
Neo-ALLTO trials, where this patient group did not benefit
from lapatinib or trastuzumab, respectively [128, 129].
Resistance can also emerge from aberration of the apopto-
sis pathways. Inhibition of driver oncogenes such as HER2
ultimately leads to apoptosis. Accordingly, expression lev-
els of the pro-apoptotic BH3-only protein Bcl-2-like pro-
tein 11 (BIM) are predictive for the response of
HER2-overexpressing breast cancer cells to HER2-target-
ing treatment. Thus, in a small patient cohort where lap-
atinib was used as a single agent treatment for metastatic
HER2+ breast cancer, low BIM expression levels before
treatment correlated with inefficient treatment due to in-
adequate apoptotic response [130, 131]. Moreover, resis-
tance against HER2-targeted treatment in HER2+ breast
cancers involves anti-apoptotic Bcl-2 as well as pro-apop-
totic BH3-only family members. Accordingly, Bcl-2 is up-
and Bax downregulated in trastuzumab-resistant breast
cancer cells [132]. As already mentioned, several links be-
tween apoptosis and autophagy exist, indicating crosstalk
between the two pathways [133]. The aberrant expression
of proteins is thus involved in apoptosis influence as well
autophagy activity. The anti-apoptotic protein Bcl-2 is of-
ten upregulated in tumours. Through binding and subse-
quent sequestration of the autophagy protein Beclin-1,
Bcl-2 can negatively regulate autophagy initiation [27].
High Bcl-2 levels can allow co-existence of low apoptosis
as well as low autophagy. The pro-apoptotic Bcl-2 family
member Bax can negatively regulate autophagy initiation
through caspase-mediated cleavage of Beclin-1 as well
[134]. This connection would indicate that activation of
apoptosis results in autophagy suppression. Additionally,
Bcl-2 family members regulate a non-canonical form of
autophagy leading to necroptosis, an apoptosis-indepen-
dent form of programmed cell death [135]. Here the au-
tophagy machinery serves as a scaffold for the formation of
the cell death-inducing signalling complex, the necrosome
[136].
Resistance mechanisms against HER2-targeting treatment
are multifaceted. Some of them include an aberration of
the receptor itself, whereas others bypass HER2 signalling.
Examples are the overexpression of other tyrosine kinase
receptors or constitutive activation of downstream targets
[111]. Resistance may arise from aberrations in the apop-
tosis pathway as well. As apoptosis and autophagy are in-
terconnected pathways, expression levels of apoptosis pro-
teins may also influence autophagic flux. However, the
connection between the pathways is complex and not yet
fully understood [69].
HER2 and autophagy – possible candidates for
combination therapy?
HER2-targeted therapies are best studied in breast cancer.
However, they are also approved for the treatment of
HER2+ gastric cancer and tumours of the gastro-oe-
sophageal junction and can be applied off-label for
HER2-positive oesophageal adenocarcinoma [137]. De-
creased autophagy supports the development of HER2+
breast cancer. Firstly, an association between the loss of the
tumour suppressor and autophagy protein Beclin-1 with
HER2 gene amplification was found [138]. Secondly, de-
creased Beclin-1 mRNA expression in mammary tumours
is not only associated with worse disease-free survival but
is also more common in HER2+ breast cancer [139]. Sup-
porting these notions, a study investigating human and
mouse breast cancer cells found that low Beclin-1 mRNA
levels correlate with HER2 overexpression, and that
HER2-amplified tumours exhibit a low autophagy gene
expression signature, independent of Beclin-1 mRNA ex-
pression. Results from xenograft experiments in this study
suggest that in HER2+ tumours autophagy is downreg-
ulated even in a Beclin-1 wild type background [140].
Moreover, it was found that HER2 directly interacts with
Beclin-1 in breast cancer cells, and that this interaction in-
hibits autophagy. Disruption of this interaction with Tat-
Beclin-1, an autophagy-inducing peptide, caused a cessa-
tion of tumour growth in xenograft models [141].
During breast cancer therapy, autophagy has been shown to
support resistance to chemotherapeutic agents [142–144].
Similarly, in the context of HER2-targeting treatment, au-
tophagy is mainly discussed as a resistance mechanism.
An analysis of a large collection of breast cancer cell lines
showed that the transcript levels of ATG12 were upreg-
ulated in trastuzumab-non-responsive HER2-overexpress-
ing cells as compared with treatment-sensitive cell lines
[145]. Furthermore, trastuzumab-resistant breast cancer
spheroids are characterised by increased autophagic activ-
ity and show increased sensitivity to autophagy inhibition
[146, 147]. Similarly, breast cancer cells rendered resistant
to lapatinib exhibited an activation of autophagy and could
be re-sensitised to the drug by autophagy inhibition [148,
149]. In our group, we observed a similar phenomenon
for HER2-amplified oesophageal adenocarcinoma (EAC)
cells. In a lapatinib-resistant EAC cell line (OE19LapR)
we observed a general upregulation of basal autophagy
levels compared to the parental cell line (OE19P). Upon
autophagy inhibition, OE19LapR could be re-sensitised
to lapatinib treatment to the level of parental cells [150].
We were able to corroborate these findings by growing
both cell lines in a chick chorioallantoic membrane (CAM)
xenograft assay. The CAM assay is a 3D in ovo cell culture
model, where tumour cells are grown in a scaffold on
an extraembryonic membrane of the chick embryo [151].
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Generally, OE19LapR cells formed microtumours that
contained more cells, were more vascularised and less
necrotic. LC3B and p62 dot formation compared to a ho-
mogeneous staining is considered to be an indication for
active autophagy in IHC [152]. In the microtumours
formed by our two EAC cell lines, OE19LapR and OE19P,
higher autophagy levels were indicated by dot-like staining
in the OE19LapR tumours compared to the OE19P tu-
mours, where the staining was more homogenous (fig. 3).
Conversely, a recent study in gastric cancer cells reported
inhibition of autophagic flux upon trastuzumab treatment.
A pool of resistant cancer cells showed lower basal levels
of autophagy than the parental cells, and autophagy inhibi-
tion induced more cell death in the parental cell line than
in the trastuzumab refractory cells [153]. Moreover, the ac-
tivation of autophagy in the context of HER2 inhibitor re-
sistance is discussed as part of a metabolic shift in resistant
cells. Trastuzumab-resistant breast cancer cells with upreg-
ulated autophagy were shown to have a significantly high-
er expression of the catalytic subunit of AMPK, AMPKα1
[154, 155]. Cells treated with receptor tyrosine kinase in-
hibitors activate AMPK as a response to growth factor de-
privation, which leads, among other effects, to the inhibi-
tion of protein synthesis. This is lethal to HER2-amplified
breast cancer cells depending on glycolysis [156]. AMPK
not only coordinates the adaptive response to ATP deple-
tion but also modulates the activity of autophagy regulators
such as ULK1 and mTOR [157]. Thus, increased activity
of AMPK could result in a shift to catabolism and prepare
cells resistant to HER2 inhibition to activate protective au-
tophagy and overcome the acute bioenergetic crisis result-
ing from HER2 inhibition [158]. Current data on the role of
autophagy in HER2+ tumour formation and possible resis-
tance against HER2 inhibition are not fully conclusive and
the role of autophagy in the formation and progression of
HER2+ carcinogenesis warrants further studies [159, 160].
On the basis of several preclinical studies demonstrating
the antineoplastic effect of autophagy inhibition in combi-
nation with a variety of anticancer treatments, first phase I
clinical trials studying the safety and antineoplastic effect
of the autophagy inhibitors chloroquine and hydroxy-
chloroquine were conducted. In 2014, it was shown that
hydroxychloroquine could be safely combined with cyto-
toxic chemotherapeutics [68, 161, 162]. First clinical re-
sults of studies including chloroquine or hydroxychloro-
quine for anticancer treatment in combination with
standard treatment are promising [163]. At the moment
there are no clinical trials involving hydroxychloroquine in
HER2+ cancers. However, there are several clinical trials
investigating the effect of hydroxychloroquine on breast
cancer. One of them is the CLEVER pilot trial, which is a
phase II trial of hydroxychloroquine in combination with
everolimus, an mTOR inhibitor, for the prevention of re-
current breast cancer (NCT03032406). The GLACIER tri-
al is testing the efficacy of gedatolisib (a PI3K/mTOR in-
hibitor) and hydroxychloroquine on early recurrent breast
cancer (NCT03400254). Another study is investigating the
efficacy of hydroxychloroquine in metastatico estrogen-re-
ceptor-positive breast cancer that has progressed after hor-
monal therapy (NCT02414776).
Various pieces of evidence suggest a connection between
autophagy and HER2. The autophagy-initiating protein
Beclin-1 was shown to be low-expressed in HER2+ breast
cancer. Moreover, independent of Beclin-1 expression,
HER2+ breast cancer cells were shown to exhibit low ex-
pression of ATGs. Additionally, the direct interaction of
Beclin-1 and HER2 was shown to influence autophagy ac-
tivity [141]. In the context of resistance to HER2-target-
Figure 3: Increased autophagy in lapatinib-resistant OE19 oesophageal cancer cells. Microtumours developed from OE19 parental
(OE19P) and OE19 lapatinib-resistant (OE19LapR) cells are shown in the upper and lower panels, respectively. Depicted from left to right are:
H&E, p62 and LC3B staining. Lapatinib-resistant OE19 cells display p62 and LC3B dot formation indicative of increased autophagic activity
compared to the parental cell line. The staining intensity of p62 corresponds to a score of 3+ and of LC3B to a score of 2+, according to
Schläfli et al. [152].H&E = haematoxylin and eosin; p62 = sequestosome 1, SQSTM1; LC3B = microtubule-associated protein light chain 3B
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ed treatment, autophagy is often reported as a resistance
mechanism upregulated in resistant cells. Some of these
studies showed that autophagy inhibition led to a re-sen-
sitisation to HER2-targeting drugs [148]. The results from
previous clinical studies with hydroxychloroquine, indi-
cate that the inhibition of autophagy might be a valuable
new avenue for breast cancer treatment. Clearly, there is
a need for more specific and potent autophagy inhibitors.
Clinical trials investigating the inhibition of autophagy in
HER2+ breast cancer are still lacking, but results from on-
going trials in other breast cancer subtypes and the above-
mentioned preclinical data might drive research in the di-
rection of combining autophagy inhibition with
HER2-targeting treatment in HER2-amplified cancers.
Concluding remarks
Generally, the role of macroautophagy in tumour devel-
opment, progression and resistance formation against can-
cer therapy is ambivalent [46]. The HER2 oncogene is
overexpressed in different tumour types, and drugs specif-
ically targeting this receptor tyrosine kinase have been
successfully applied in cancer therapy [98]. However, pro-
gression and resistance formation against these drugs ul-
timately occurs. Resistance mechanisms are multifaceted,
and ways to prevent or overcome resistance are urgently
needed [159]. Beclin-1, an autophagy initiating protein
was reported to directly interact with HER2. Moreover,
this interaction was shown to influence autophagy activity
[141]. Additionally, Beclin-1 expression was reported to be
lower in HER2+ tumours. In the context of resistance to
HER2-targeting treatments, autophagy was reported to be
upregulated. Even though contradictory data exists, most
in vitro studies report an upregulation of autophagy in re-
sistant cells, which can be abrogated to some extent by in-
hibiting autophagy [145, 147, 148]. Still, the understanding
of autophagy’s role in the development and progression of
HER2+ cancers is in its infancy. Future studies deciphering
the networks connecting HER2 and autophagy are there-
fore needed. Two autophagy-inhibiting agents, chloro-
quine and hydroxychloroquine, are available for clinical
application. They have been evaluated for cancer treatment
alone and in different combinations in a number of clinical
trials. However, it is not yet known whether the beneficial
effects observed during hydroxychloroquine and chloro-
quine treatment are based on their autophagy inhibition
function or on their effects on other pathways [64]. More-
over, the inhibitory effect of hydroxychloroquine on the
lysosome could lead to defective lysosomal function and
thus cause lysosomal storage disease [164, 165]. The de-
velopment of specific autophagy inhibitors is still in an
early phase, but using conditional ATG knockout animals
it has been shown that systemic inhibition of essential
autophagy genes is possible during a certain therapeutic
window [166]. In addition, a better understanding of the
crosstalk between autophagy and apoptosis could help to
shape the development of new, more specific autophagy
targeting agents for antineoplastic treatment. With im-
proved autophagy inhibitors and a better understanding of
the processes involved, new quests will undoubtedly arise,
such as the search for better and more reliable biomarkers
as indicators of macroautophagic flux in human tissue. The
combination of LC3B and p62 has been proposed as an ap-
proximate approach to characterising different autophagy
status in tissue samples [152, 167]. However, other marker
proteins such as Beclin-1, ULK1 or ATG5 have also been
used to detect autophagy in tissue via IHC (excellently
reviewed in [168]). One issue of these attempts to as-
sess autophagy via IHC is that the expression of some au-
tophagy-related proteins does not change upon autophagy
induction. Moreover, the expression levels of these pro-
teins are cell-type and tissue-specific, and since most au-
tophagy related genes are also involved in other cellular
pathways, an autophagy specific marker or marker com-
bination has not yet been identified. For future studies on
autophagy-targeting therapies, however, such biomarkers
would be of great value in deciding which tumours should
be treated with autophagy-inhibiting or possibly even au-
tophagy-inducing agents.
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